Previous 10 | Next 10 |
BOSTON , May 26, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCa...
BOSTON , May 13, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCa...
Stealth BioTherapeutics Corp (MITO) Q1 2020 Earnings Conference Call May 7, 2020 08:30 ET Company Participants Henry Hess - Chief Legal Counsel Reenie McCarthy - Chief Executive Officer Rob Weiskopf - Chief Financial Officer Jim Carr - Chief Clinical Development Officer Brian...
Image source: The Motley Fool. Stealth BioTherapeutics Corp (NASDAQ: MITO) Q1 2020 Earnings Call May 8, 2020 , 8:30 p.m. ET Operator Continue reading
Stealth BioTherapeutics (NASDAQ: MITO ): Q1 GAAP EPS of -$0.04 beats by $0.06 . More news on: Stealth BioTherapeutics Corp, Earnings news and commentary, Healthcare stocks news, , Read more ...
BOSTON , May 7, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results...
BOSTON , May 4, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will re...
Nano cap Stealth BioTherapeutics ( MITO ) has completed the direct sale of ~153M ordinary shares at $0.13084 per share to Morningside Venture Investments Limited. More news on: Stealth BioTherapeutics Corp, Healthcare stocks news, Stocks on the move, , Read more ...
BOSTON , April 13, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has comple...
Exact Sciences (NASDAQ: EXAS ) initiated with Outperform rating and $70 (25% upside) price target at Evercore ISI. More news on: Exact Sciences Corporation, Health Catalyst, Inc., Intercept Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...